218 related articles for article (PubMed ID: 31455429)
41. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
[TBL] [Abstract][Full Text] [Related]
42. Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy.
Spear TT; Evavold BD; Baker BM; Nishimura MI
Cancer Immunol Immunother; 2019 Nov; 68(11):1881-1889. PubMed ID: 31595324
[TBL] [Abstract][Full Text] [Related]
43. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
Bobisse S; Rondina M; Merlo A; Tisato V; Mandruzzato S; Amendola M; Naldini L; Willemsen RA; Debets R; Zanovello P; Rosato A
Cancer Res; 2009 Dec; 69(24):9385-94. PubMed ID: 19996290
[TBL] [Abstract][Full Text] [Related]
44. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
45. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
46. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning.
Aarnoudse CA; Krüse M; Konopitzky R; Brouwenstijn N; Schrier PI
Int J Cancer; 2002 May; 99(1):7-13. PubMed ID: 11948485
[TBL] [Abstract][Full Text] [Related]
47. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
Kalaora S; Wolf Y; Feferman T; Barnea E; Greenstein E; Reshef D; Tirosh I; Reuben A; Patkar S; Levy R; Quinkhardt J; Omokoko T; Qutob N; Golani O; Zhang J; Mao X; Song X; Bernatchez C; Haymaker C; Forget MA; Creasy C; Greenberg P; Carter BW; Cooper ZA; Rosenberg SA; Lotem M; Sahin U; Shakhar G; Ruppin E; Wargo JA; Friedman N; Admon A; Samuels Y
Cancer Discov; 2018 Nov; 8(11):1366-1375. PubMed ID: 30209080
[TBL] [Abstract][Full Text] [Related]
48. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
[TBL] [Abstract][Full Text] [Related]
49. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
50. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
51. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
52. Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function.
Thomas S; Mohammed F; Reijmers RM; Woolston A; Stauss T; Kennedy A; Stirling D; Holler A; Green L; Jones D; Matthews KK; Price DA; Chain BM; Heemskerk MHM; Morris EC; Willcox BE; Stauss HJ
Nat Commun; 2019 Oct; 10(1):4451. PubMed ID: 31575864
[TBL] [Abstract][Full Text] [Related]
53. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
Roszik J; Haydu LE; Hess KR; Oba J; Joon AY; Siroy AE; Karpinets TV; Stingo FC; Baladandayuthapani V; Tetzlaff MT; Wargo JA; Chen K; Forget MA; Haymaker CL; Chen JQ; Meric-Bernstam F; Eterovic AK; Shaw KR; Mills GB; Gershenwald JE; Radvanyi LG; Hwu P; Futreal PA; Gibbons DL; Lazar AJ; Bernatchez C; Davies MA; Woodman SE
BMC Med; 2016 Oct; 14(1):168. PubMed ID: 27776519
[TBL] [Abstract][Full Text] [Related]
54. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
55. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
[TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes.
Hanagiri T; Shigematsu Y; Kuroda K; Baba T; Shiota H; Ichiki Y; Nagata Y; Yasuda M; So T; Takenoyama M; Tanaka F
Cancer Sci; 2012 Aug; 103(8):1414-9. PubMed ID: 22621620
[TBL] [Abstract][Full Text] [Related]
57. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
[TBL] [Abstract][Full Text] [Related]
58. The reciprocal regulation loop of Notch2 pathway and miR-23b in controlling gastric carcinogenesis.
Huang TT; Ping YH; Wang AM; Ke CC; Fang WL; Huang KH; Lee HC; Chi CW; Yeh TS
Oncotarget; 2015 Jul; 6(20):18012-26. PubMed ID: 26041881
[TBL] [Abstract][Full Text] [Related]
59. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
60. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]